DBV Technologies S.A. (NASDAQ:DBVT) has earned a consensus rating of “Buy” from the six research firms that are currently covering the stock. Six equities research analysts have rated the stock with a buy recommendation. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $45.80.
A number of equities research analysts recently issued reports on DBVT shares. Zacks Investment Research raised shares of DBV Technologies from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a report on Tuesday, November 8th. Jefferies Group LLC set a $47.00 price objective on shares of DBV Technologies and gave the company a “buy” rating in a report on Monday, October 24th.
A number of hedge funds and other institutional investors have recently made changes to their positions in DBVT. Royal Bank of Canada raised its position in shares of DBV Technologies by 115.8% in the second quarter. Royal Bank of Canada now owns 4,100 shares of the company’s stock valued at $133,000 after buying an additional 2,200 shares during the period. Tocqueville Asset Management L.P. raised its position in shares of DBV Technologies by 22.0% in the second quarter. Tocqueville Asset Management L.P. now owns 25,000 shares of the company’s stock valued at $816,000 after buying an additional 4,500 shares during the period. TimesSquare Capital Management LLC raised its position in shares of DBV Technologies by 0.6% in the third quarter. TimesSquare Capital Management LLC now owns 990,503 shares of the company’s stock valued at $35,985,000 after buying an additional 5,950 shares during the period. BlackRock Institutional Trust Company N.A. bought a new position in shares of DBV Technologies during the second quarter valued at $232,000. Finally, TD Asset Management Inc. bought a new position in shares of DBV Technologies during the third quarter valued at $272,000. 48.98% of the stock is owned by institutional investors.
DBV Technologies (NASDAQ:DBVT) opened at 35.58 on Friday. DBV Technologies has a 12 month low of $22.55 and a 12 month high of $37.98. The stock has a 50 day moving average of $35.10 and a 200-day moving average of $35.35. The stock’s market cap is $1.64 billion.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.